PolyPid Goodwill and Intangible Assets 2019-2025 | PYPD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

PolyPid goodwill and intangible assets from 2019 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

PolyPid goodwill and intangible assets from 2019 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$70B
Zoetis (ZTS)	$68.3B
Takeda Pharmaceutical (TAK)	$47.7B
Daiichi Sankyo, - (DSNKY)	$47.6B
BeOne Medicines - (ONC)	$35.2B
Sandoz Group AG (SDZNY)	$26.1B
Summit Therapeutics (SMMT)	$19.8B
Merck (MKKGY)	$17.1B
Shionogi (SGIOY)	$15.2B
United Therapeutics (UTHR)	$14.1B
Neurocrine Biosciences (NBIX)	$13.2B
Orion OYJ (ORINY)	$10.8B
IPSEN (IPSEY)	$10.6B
Eisai (ESAIY)	$9.2B
Madrigal Pharmaceuticals (MDGL)	$8.2B
Corcept Therapeutics (CORT)	$7.6B
Grifols, S.A (GRFS)	$7.4B
Ionis Pharmaceuticals (IONS)	$7B
Stevanato Group S.p.A (STVN)	$6.9B
Hikma Pharmaceuticals Plc (HKMPF)	$5.3B
Ono Pharmaceutical (OPHLF)	$5.1B
Soleno Therapeutics (SLNO)	$3.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$3B
Crinetics Pharmaceuticals (CRNX)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.8B
Hypermarcas (HYPMY)	$2.7B
Catalyst Pharmaceuticals (CPRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.4B
Ocular Therapeutix (OCUL)	$2.2B
Endo (NDOI)	$1.8B